PyrAmes raises $6m for continuous blood pressure monitoring products

US-based digital healthcare company PyrAmes, which is focused on manufacturing continuous blood pressure monitoring products, has raised $6 million in a Series A round.

The funding round was led by GSR Ventures, and had seen participation from Keytone Ventures, and XTX Ventures among other investors.

Xina Quan – Co-Founder and CEO of PyrAmes said: “We are very pleased to secure this financing, which will accelerate the commercialization of our novel products for the benefit of both patients and clinicians.

“We are also thrilled to have the support of experienced digital healthcare investors such as GSR Ventures, Keytone Ventures and XTX Ventures, and world-renowned clinicians such as Dr. Thomas Fogarty, Dr. Thomas Krummel, and Dr. Peter Fitzgerald, as we develop our innovative platform.”

PyrAmes intends to use proceeds from the Series A round for further developing its technology by means of pilot-scale manufacturing, clinical validation studies, and also regulatory agency reviews.

Its lead product is Boppli, which has been designed for infants in the neonatal intensive care unit (NICU) has a breakthrough device designation from the US Food and Drug Administration (FDA). Currently, the only way for getting continuous blood pressure measurements in the NICU is by inserting an arterial catheter, which is invasive and can result in severe complications.

Boppli is a wireless sensor band that can be placed easily around the wrist or foot of babies for continuously measuring blood pressure. PyrAmes has planned to develop follow-on products for adults in inpatient as well as for at-home settings.